The acquisition expands Evotec's drug discovery and early development solutions for pharma and biotechnology companies. CCS' large-scale processes for cell production, freezing and storage, as well as the team of specialized cell culture scientists and technicians, will be fully integrated into Evotec's Hamburg operations.
"Through the acquisition of CCS, Evotec strengthens its cell culture capabilities and gains access to a growing base of customers using cell- based assays in their drug discovery processes. CCS' experience and technologies for large scale cell production are a perfect fit with Evotec's screening and in vitro pharmacology activities,” said Dr. Mario Polywka, chief operating officer of Evotec AG.
Dr. Oliver Wehmeier, chief executive officer of CCS, said, "We are excited to join forces with Evotec. Our portfolio of custom products perfectly complements Evotec's integrated service offering. In return, our customers, who have relied on CCS' products and services for many years, will gain access to Evotec's broad range of screening technologies, which add a tremendous value to the assay-ready cells and cell-based reagents we provide."